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Edited by Hans-Dieter KlenkAbstract In the present study, we identiﬁed the human heat
shock protein 60 (HSP60) epitope responsible for binding to
macrophages. Studies using overlapping 15- and 20-mer peptides
of the human HSP60 sequence to compete with binding of
HSP60 to macrophages indicated that surface binding was
accounted for by the region aa481–500. Deletion mutants of
HSP60, lacking the N-terminal 137, 243 or 359 amino acids,
strongly inhibited HSP60 binding to macrophages. Monoclonal
antibodies addressing regions aa1–200, aa335–366 or aa383–447
did not block HSP60 binding. We conclude that a single C-
terminal region, aa481–500, accounts for the binding of HSP60
to macrophages.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Heat shock protein (HSPs) are highly conserved proteins
expressed in all pro- and eukaryotic cells. They play important
roles in the correct processing of newly synthesized proteins [1]
and exert cytoprotective functions such as preventing the ag-
gregation of denatured proteins, initiating their refolding or
proteolytic degradation [2]. Under unphysiological conditions
like high temperature, viral or bacterial infections, cellular
HSP synthesis is upregulated [2].
Recently, the HSP60, HSP70, and HSP90 subfamilies have
attracted increasing attention because of their potential roles
in immunologically relevant processes. Several studies have
identiﬁed HSPs as targets of immune responses during mi-
crobial infections [3,4]. Because of the high sequence homol-
ogy between microbial HSPs and endogenous HSPs derived
from damaged or stressed tissue, immunological cross-reac-
tivity was suggested to contribute to the development of au-* Corresponding author. Fax: +49-211-3382-606.
E-mail address: christiane.habich@ddﬁ.uni-duesseldorf.de
(C. Habich).
Abbreviations: HSP, heat shock protein; IL, interleukin; gp96, glyco-
protein 96; BSA, bovine serum albumin; mAbs, monoclonal antibod-
ies; BLU, Boehringer luminescence units; TLR, toll-like receptor
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diabetes [5,6].
Furthermore, human HSP60 has been reported to induce
pro-inﬂammatory reactivity in human and murine innate
immune cells [7–9]. This response includes the release of the
inﬂammatory mediators tumor necrosis factor a, nitric oxide,
and interleukin-6 (IL-6). In addition, HSP60 was found to
induce gene expression of the cytokines IL-12(p70) and IL-15,
promoting a T helper 1 phenotype [7]. These ﬁndings suggest
a role of HSP60 as danger signal for the innate immune
system.
Recently, we have characterized the binding receptor for
human HSP60 on macrophages. Binding of ﬂuorescence-
labeled HSP60 was found to be saturable, occurred with sub-
micromolar aﬃnity and could be competed by unlabeled
HSP60 [10]. Furthermore, we could demonstrate that pro- and
eukaryotic HSP60 species bind to diﬀerent sites on macro-
phages. Interestingly, this study indicated that HSP60 mole-
cules of most mammalian species, including human, mouse
and rat, share the same binding site on macrophages, with
identical competition characteristics [11]. Moreover, our data
indicate that the binding receptor for HSP60 is diﬀerent from
the common receptor for HSP70, HSP90 and glycoprotein 96
(gp96), recently identiﬁed as the a2-macroglobulin receptor
[10,12–14].
So far, the potential epitope(s) on the HSP60 molecule for
receptor binding on macrophages are unknown. Therefore,
the present study was designed to identify the epitope of
HSP60, which is responsible for binding to the receptor on
macrophages. Our results identiﬁed the C-terminal region of
aa481–500 as the single HSP60 epitope involved in receptor
binding.2. Materials and methods
2.1. Cell lines
The mouse macrophage cell line J774A.1 was purchased from the
German Collection of Microorganisms and Cell Culture (Braun-
schweig, Germany) and was cultured as described previously [10].
2.2. Reagents
Recombinant human HSP60 was obtained from Peptor Inc. (Re-
hovot, Israel). A complete set of overlapping peptides of 20 amino
acids, spanning the sequence of the unprocessed precursor of humanblished by Elsevier B.V. All rights reserved.
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of Immunohematology and Blood Transfusion (Leiden University
Medical Center, Leiden, The Netherlands). Selected overlapping 15-
mer peptides, covering the region aa471–510 of the human HSP60
sequence (GenBank M22382), were synthesized by automated simul-
taneous multiple peptide synthesis as described previously [15]. A
modiﬁed peptide, pep481–500 (Ile490!Ala490, Ser497!Gly497,
Ser499!Gly499), was synthesized by Biotrend (Cologne, Germany).
Mutants of human HSP60, N-terminally deleted and covering the
human HSP60 sequence from aa138–573, aa244–573 or aa360–573,
were prepared by the following method. The nucleotide sequences of
the human HSP60 deletions were ampliﬁed from plasmid pGA8, en-
coding human HSP60, using human HSP60 oligonucleotide primers.
The PCR product was ligated into a pQE60 vector (Qiagen, Dorking,
Surrey, UK), which was subsequently transfected into Escherichia coli
ultracompetent XL-2 blue cells (Stratagene, Cambridge, UK) using a
heat shock method [16]. Bovine serum albumin (BSA) was from Sigma
(Deisenhofen, Germany). Murine anti-human HSP60 monoclonal
antibodies (mAbs) were from StressGen Biotechnologies (Victoria,
Canada; clone LK1), Dianova (Hamburg, Germany; clone 4B9/89)
and BD Transduction Laboratories (San Diego, CA; clone 24). Goat
anti-mouse IgG antibody was used as isotype control for all murine
mAbs (Sigma).2.3. Protein labeling
Labeling of human HSP60 with ﬂuorescence dye was performed as
described previously [10] using the Alexa Fluor488 Protein Labeling
kit (Molecular Probes, Leiden, The Netherlands).2.4. HSP60 binding and inhibition studies
Binding and inhibition studies were performed as described pre-
viously [10]. Brieﬂy, J774A.1 cells (1 106 cells/ml) were incubated
in a total volume of 100 ll in the presence of HSP60–Alexa488 for
45 min on ice for the binding studies. Subsequently, cells were
washed with PBS/1% BSA and resuspended in PBS containing 1%
paraformaldehyde. For the inhibition studies the macrophages were
preincubated with unlabeled HSP60, the diﬀerent peptides or HSP60
mutants in the indicated concentrations for 30 min at 4 C. Then,
HSP60–Alexa488 was added and the incubation was continued for
another 45 min on ice. In experiments using diﬀerent anti-HSP60
antibodies, HSP60–Alexa488 was preincubated together with the
mAbs for 30 min at room temperature, the mixture was added to
the cells and incubation was continued for another 45 min on ice.
After washing and ﬁxation steps, the samples were evaluated using a
FACSCalibur ﬂow cytometer (BD Bioscience, Rockville, CA). Cell
surface binding of HSP60–Alexa488 was calculated using the geo-
metric mean ﬂuorescence value after subtracting the autoﬂuores-
cence of the cells.2.5. Dot blot analysis
For dot blot analysis 140 ng human HSP60 or 7.5 lg of single 20-
mer peptides with 10aa overlap corresponding to the regions aa321–
380 or aa471–560 of human HSP60 were spotted onto Hybond ECL
membranes (Roche Diagnostics, Mannheim, Germany). After
blocking in 5% skimmed milk solution, membranes were incubated
with murine anti-human HSP60 antibody clone 4B9/89 (0.2 lg/ml,
overnight). In another approach antibody clone 4B9/89 (0.5 lg/ml)
was preincubated with a mixture of 20-mer peptides (1 lM) covering
the regions aa141–230, aa321–380 or aa471–560, with the individual
20-mer peptides (10 lM) or with PBS (control) for 1 h.
Subsequently, these mixtures were incubated with human HSP60
dotted onto membranes for 30 min. The detection was performed
with rabbit peroxidase-labeled anti-mouse IgG antibody (1 lg/ml, 45
min, DakoCytomation, Hamburg, Germany) using the ECL
detection system (Amersham Pharmacia Biotech, Freiburg, Ger-
many). Quantitative analysis was performed by Lumi-Imager (Bo-
ehringer, Mannheim) and shown as Boehringer luminescence units
(BLU).2.6. Statistical analysis
Data were expressed as mean values S.D. Statistical analysis was
performed using the Student’s t test, two-tailed. Diﬀerences were
considered statistically signiﬁcant with P < 0:05.3. Results
3.1. Identiﬁcation of the HSP60 binding epitope by inhibition
studies with HSP60 peptides
Inhibition experiments with a complete set of overlapping
20-mer peptides, covering the human HSP60 sequence from
aa1–560, were performed to identify regions of the molecule
involved in surface binding to macrophages. Peptides were
screened at 125 lM concentration for inhibiting binding of
ﬂuorescence-labeled human HSP60 (HSP60–Alexa488) to cells
of the mouse macrophage line J774A.1. At this high concen-
tration, only one peptide corresponding to aa481–500,
pep481–500, was found to induce strong inhibition of HSP60–
Alexa488 binding, i.e., more than 50% (Fig. 1). A more de-
tailed analysis using pep471–490, pep481–500 and pep491–510
showed that only pep481–500 resulted in a signiﬁcant
(P < 0:05) dose-dependent reduction of HSP60–Alexa488
binding to J774A.1 cells to 28% at a concentration of 125 lM
(Fig. 2). The adjacent peptides, pep471–490 and pep491–510,
did not compete with HSP60–Alexa488 binding.
To exclude that the observed inhibitory eﬀect of pep481–500
is mediated by speciﬁc conformational properties of the 20-mer
peptide, we further analyzed the eﬀect of selected 15-mer
peptides, covering the region around the potential binding
epitope of HSP60, aa471–510 (Fig. 3). Only one peptide,
pep481–495, interfered with binding of HSP60–Alexa488 to
J774A.1 macrophages, but to a lesser extent as pep481–500
(51% versus 28% HSP60–Alexa488 binding). None of the ad-
jacent peptides, i.e., pep471–485, pep476–490, pep486–500,
pep491–505 and pep496–510, blocked HSP60 binding. Fur-
thermore, when testing pep481–500, modiﬁed at amino acid
positions 490, 497 and 499, the inhibitory eﬀect of the peptide
was almost lost (72% versus 21% inhibition of HSP60–
Alexa488 binding). Taken together, these results indicate that
the region aa481–500 of the HSP60 molecule is responsible for
the binding of HSP60 to macrophages.
3.2. Mapping of the HSP60 binding epitope by HSP60 deletion
mutants
The ﬁndings obtained with peptides were further supported
by the use of three diﬀerent deletion mutants of human HSP60.
All mutants had a preserved region aa481–500, but were de-
leted for the N-terminal 137, 243 or 359 amino acids. When
testing these HSP60 mutants at a concentration of 3.5 lM for
inhibiting binding of HSP60–Alexa488 to J774A.1 macro-
phages, all three mutants led to a considerable reduction of
HSP60 binding, i.e., mean ﬂuorescence intensity of the cells
decreased from 9.1 to 5.4 (Fig. 4). This corresponds to an in-
hibitory eﬀect of these three HSP60 mutants on HSP60–
Alexa488 binding in the range of 57–62%, thereby conﬁrming
the location of the binding epitope in the C-terminal region of
HSP60.
3.3. Mapping of the HSP60 binding epitope by antibodies
Finally, we investigated the eﬀect of commercially available
mAbs, directed against diﬀerent epitopes of the native human
HSP60 protein, i.e., clone 24 (aa1–200), clone 4B9/89 (aa335–
366 or aa484–547) or clone LK1 (aa383–447), on the binding
of HSP60–Alexa488 to J774A.1 macrophages (Table 1). When
analyzing these antibodies at concentrations of 8 and 20 lg/ml
in the binding assay, none of them competed with the binding
of HSP60–Alexa488 to the cells.
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Fig. 1. Eﬀect of 20-mer peptides on HSP60 binding. J774A.1 cells were preincubated with diﬀerent 20-mer peptides (125 lM, 30 min). Subsequently,
350 nM HSP60–Alexa488 was added and incubation was continued for another 45 min on ice. The analysis was performed by ﬂow cytometry.
Inhibition of HSP60–Alexa488 binding is indicated as %.
Binding of
HSP60-Alexa488
(%)
481KNAGVEGSLIVEKIMQSSSE500
471TLKIPAMTIAKNAGV485
476AMTIAKNAGVEGSLI490
481KNAGVEGSLIVEKIM495
486EGSLIVEKIMQSSSE500
491VEKIMQSSSEVGYDA505
496QSSSEVGYDAMAGDF510
28 ± 2
104 ± 12
110 ± 4
51 ± 11
100 ± 3
110 ± 3
110 ± 6
481KNAGVEGSLAVEKIMQGSGE500 79 ± 2
Peptides
Fig. 3. Eﬀect of selected 15-mer and 20-mer peptides on HSP60
binding. J774A.1 cells were preincubated 30 min with 125 lM of the
diﬀerent unlabeled 15-mer or 20-mer peptides, followed by incubation
with 350 nM HSP60–Alexa488 (45 min on ice). The analysis was
performed by ﬂow cytometry. Binding of HSP60–Alexa488 is indicated
as %. Error bars represent means S.D. of two to three independent
experiments. Amino acids exchanged in comparison to the original
sequence of pep481–500 are underlined.
*
*
*
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*
*
*
*
Autofluorescence
HSP60*
1.75 µM HSP60 + HSP60*
3.5 µM HSP60 + HSP60*
1.75 µM pep481-500 + HSP60*
3.5 µM pep481-500 + HSP60*
10 µM pep481-500 + HSP60*
30 µM pep481-500 + HSP60*
50 µM pep481-500 + HSP60*
125 µM pep481-500 + HSP60*
3.5 µM pep471-490 + HSP60*
125 µM pep471-490 + HSP60*
3.5 µM pep491-510 + HSP60*
125 µM pep491-510 + HSP60*
0 25 50 75 100
Maximal binding (%)
Fig. 2. Eﬀect of selected 20-mer peptides on HSP60 binding. J774A.1
cells were incubated in the absence (autoﬂuorescence) or presence of
350 nM HSP60–Alexa488 (HSP60*) for 45 min on ice. For inhibition
studies cells were preincubated with unlabeled HSP60, pep481–500,
pep471–490 or pep491–510 at the indicated concentrations (30 min),
followed by incubation with HSP60*. The analysis was performed by
ﬂow cytometry and binding of HSP60* in the absence of inhibitors was
set 100%. Error bars represent means+S.D. of three independent ex-
periments. Signiﬁcant inhibition of binding is indicated as *, P < 0:05.
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recognize either the HSP60 region aa335–366 or the region
aa484–547 [17], including the putative binding region, we
further analyzed the epitope speciﬁcity of this antibody. Dot
blot experiments analyzing the eﬀect of mixtures of distinct 20-
mer peptides on the binding of antibody clone 4B9/89 to
HSP60 (Fig. 5A) revealed that preincubation of the peptide
mixture covering the region aa321–380 of HSP60 with anti-
body clone 4B9/89 resulted in the inhibition of antibody
binding to HSP60. Neither the mixture of peptides from a
region not recognized by the antibody (aa141–230), nor the
peptide mixture covering the region aa471–560 inhibited an-tibody binding to HSP60. Next, we investigated the eﬀect of
the individual 20-mer peptides on the binding of antibody
clone 4B9/89 to HSP60 by dot blot analysis (Fig. 5B). Prein-
cubation of pep361–380 with antibody clone 4B9/89 inhibited
binding of the antibody to HSP60, whereas none of the other
peptides interfered with antibody binding to HSP60. These
results were conﬁrmed by additional dot blot analysis with
single 20-mer peptides, which showed that only the peptide
corresponding to region aa361–380 was recognized by anti-
body clone 4B9/89 (2.06 106 BLU) in a similar intensity as
human HSP60 (2.65 106 BLU). None of the other tested 20-
Table 1
Eﬀect of anti-HSP60 antibodies on HSP60 binding to macrophages
Anti-human-HSP60 antibody Concentration
(lg/ml)
Binding of HSP60–
Alexa488 (%)
Clone Recognized
epitope
– – – 100
Clone 24 aa1–200 8 97 9
20 102 8
4B9/89 aa335–366 or
aa484–547
8
20
130 41*
125 5*
LK1 aa383–447 8 100 20
20 99 5
IgG isotype 8 111 8
Control 20 106 1
HSP60–Alexa488 (350 nM) was preincubated with the diﬀerent mAbs
(30 min) and then added to J774A.1 macrophages.
The analysis was performed by ﬂow cytometry and HSP60–Alexa488
binding in the absence of antibodies was set 100%. The data represent
meansS.D. of three independent experiments. Signiﬁcant diﬀerences
to binding of HSP60–Alexa488 are indicated as *, P < 0:05.
Fig. 5. Epitope speciﬁcity of HSP60 antibody clone 4B9/89. (A) PBS
(1), 20-mer peptide mixtures (1 lM), covering the regions aa141–230
(2), aa321–380 (3) or aa471–560 (4) of the human HSP60 molecule or
(B) PBS (1) or individual 20-mer peptides (10 lM), covering the re-
gions aa321–380: pep321–340 (2), pep331–350 (3), pep341–360 (4),
pep351–370 (5), pep361–380 (6) and region aa471–560: pep471–490
(7), pep481–500 (8), pep491–510 (9), pep501–520 (10), pep511–530
(11), pep521–540 (12), pep531–550 (13), pep541–560 (14) of the human
HSP60 molecule, were preincubated with murine anti-human HSP60
antibody clone 4B9/89 (0.5 lg/ml) for 1 h. Subsequently these mixtures
were incubated on membranes spotted with HSP60 (140 ng) for 30
min. After incubation with peroxidase-labeled rabbit anti-mouse IgG
antibody (1 lg/ml, 45 min), blots were developed using ECL substrate.
Fig. 4. Eﬀect of selected HSP60 deletion mutants on HSP60 binding.
J774A.1 cells were incubated in the absence (autoﬂuorescence) or
presence of 350 nM HSP60–Alexa488 (HSP60*) for 45 min on ice. For
inhibition studies cells were preincubated (30 min) with 3.5 lM unla-
beled HSP60 or 3.5 lM of the unlabeled HSP60 mutants (aa138–573,
aa244–573 or aa360–573), followed by incubation with HSP60*. The
analysis was performed by ﬂow cytometry and ﬂuorescence intensities
of the cells (x-axis) were plotted against cell counts.
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(<0.1 106 BLU). By assigning the epitope speciﬁcity of clone
4B9/89 to region aa335–366, we could conﬁrm the location of
the binding epitope of HSP60 to the C-terminal region of the
molecule.4. Discussion
When using a peptide library to characterize epitope(s) of
HSP60 involved in receptor binding on macrophages, we
identiﬁed a peptide corresponding to aa481–500 of the human
HSP60 sequence. This peptide mediated strong dose-depen-
dent inhibition of HSP60 binding to macrophages. Signiﬁcant
inhibition of binding was already reached at low micromolar
concentrations of the peptide pep481–500. No inhibitory eﬀect,
even at 125 lM, was observed for the overlapping peptides
pep471–490 or pep491–510.Based on these ﬁndings, we performed further analysis using
15-mer peptides of human HSP60 with an overlap diﬀerent
from that of the 20-mer peptides, thereby excluding that con-
formational properties of pep481–500 mediated the inhibitory
eﬀect on HSP60 binding. When analyzing the inhibitory eﬀect
of selected 15-mer peptides, covering the region 471–510 of the
human HSP60 sequence, only pep481–495 blocked HSP60
binding to J774A.1 macrophages. The inhibition of HSP60–
Alexa488 binding to the cells by pep481–495 was lower (49%)
compared to that caused by pep481–500 (72%). We obtained
further support of our ﬁndings by the use of a modiﬁed peptide
covering the region aa481–500 that lost its inhibitory eﬀect on
HSP60 binding to macrophages. At amino acid positions 497
and 499 conservative amino acid substitutions were performed
(serine! glycine), which should not lead to major alterations
of the peptide structure. By contrast, replacement of isoleucine
by alanine at position 490 leading to the loss of ethyl- and
methyl-groups, may result in an alteration of the structure or
the physical properties of the peptide, thereby abolishing its
inhibitory eﬀect. These results indicate a major contribution of
the HSP60 region around amino acid 490 to binding of HSP60
on macrophages.
As an independent proof of our ﬁndings described above, we
analyzed the eﬀect of three diﬀerent HSP60 mutants, truncated
from the N-terminal end, in our binding assay. All three
HSP60 mutants, possessing a preserved region aa481–500,
competed with HSP60–Alexa488 binding to J774A.1 macro-
phages, thereby conﬁrming that the relevant binding region on
the HSP60 molecule is located at the C-terminal region of
HSP60. Furthermore, by this approach we could exclude that
pep481–500 mediated its inhibitory eﬀect by blocking a po-
tential binding site on the N-terminal region of the HSP60
molecule up to amino acid position 359.
Further support of our ﬁndings was gained from inhibition
studies with mAbs recognizing diﬀerent regions of the native
HSP60 molecule (aa1–200, aa335–366/aa484–547, and aa383–
447). None of these antibodies interfered with HSP60 binding
to J774A.1 cells. One of these antibodies, clone 4B9/89, has
C. Habich et al. / FEBS Letters 568 (2004) 65–69 69been described to either bind to region aa335–366 or aa484–
547 of the human HSP60 sequence [17], which means that this
antibody possibly recognizes the region of interest, aa481–500.
Further mapping done here revealed that the antibody binds to
region aa335–366. Hence, these results demonstrate that the
binding region on HSP60 is localized outside the regions rec-
ognized by the analyzed antibodies. These ﬁndings together
with our results discussed above demonstrate that the binding
epitope of HSP60 to macrophages is restricted to the aa481–
500 in the C-terminal region of the HSP60 molecule.
The identiﬁcation of a speciﬁc binding epitope on the HSP60
molecule will facilitate the identiﬁcation of the macrophage
surface receptor involved, and signaling events and functional
consequences of binding. Previous studies have indicated that
toll-like receptor 4 (TLR4) and CD14 are involved in the in-
ﬂammatory signaling of HSP60 [18,19], but that TLR4 is not
involved in HSP60 binding [10]. These observations suggest
that the interaction of HSP60 with macrophages is a highly
complex process. Similar observations were made for other
HSPs. The binding receptor for the endoplasmic reticulum
resident gp96 on innate immune cells has been reported as the
a2-macroglobulin receptor, also known as CD91, whereas
gp96 signaling is TLR2/4-dependent [12–14,20]. CD91 and
CD40 have been described as binding receptors for human
HSP70 on innate immune cells [12–14,21], but CD14 [22],
TLR2, and TLR4 [23] have been found to be involved in
HSP70 signaling.
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